Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 544-546

  Lafeuillade, A ^a   Jolly, P ^a   Chadapaud, S ^a   Hittinger, G ^a   Lambry, V ^a   Philip, G ^a  

^a Hopital Chalucet Toulon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPID BLOOD LEVEL; LIPOATROPHY; METABOLIC DISORDER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

EID: 0037961088     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00018     Document Type: Letter

References (8)

1. Smith KY. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. Clin Infect Dis. 2002;185(suppl 2):S123-S127.
2. Acevedo M, Sprecher DL, Calabrese L, et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: a call for cardiovascular prevention. Atherosclerosis. 2002;163:349-354.
3. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219-1230.
4. Staszewski S, Gallant J, Pozniak A, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results [abstract LbOr17]. 14th International AIDS Conference, July 7-12, 2002; Barcelona, Spain.
5. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34:649-657.
6. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925-1931.
7. Pozniak AL, Plettenberg A, Rozenbaum W, et al. Tenofovir DF: a 48-week final analysis from a phase III randomized, double blind, placebo controlled study in antiretroviral treatment experienced patients (study 907) [abstract WeOrB1266]. 14th International AIDS Conference, July 7-12, 2002; Barcelona, Spain.
8. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. JAMA. 2002; 288:207-215.